Related Experiment Video

Updated: Nov 28, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.2K

FAM225A promotes sorafenib resistance in hepatocarcinoma cells through modulating miR-130a-5p-CCNG1 interaction

Yan Tong Liu1, Guo Qing Liu2, Jing Min Huang2

  • 1Xi'an Medical University, Xi'an, China.

Bioscience Reports
|November 27, 2020
PubMed

Insights

Long non-coding RNA FAM225A promotes hepatocellular carcinoma resistance to sorafenib. Targeting the FAM225A/miR-130a-5p/CCNG1 network may restore sensitivity to this liver cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Hepatocellular carcinoma (HCC) treatment faces challenges due to chemotherapy resistance.
  • Understanding molecular mechanisms of acquired resistance is crucial for effective liver cancer therapy.

Purpose of the Study:

  • To investigate the role of lncRNA FAM225A in sorafenib resistance in HCC.
  • To elucidate the molecular pathway involving FAM225A, miR-130a-5p, and CCNG1 in HCC drug resistance.

Main Methods:

  • Quantitative analysis of FAM225A expression in HCC tissues and cell lines.
  • FAM225A knockdown experiments in HepG2/SOR cells and in vivo tumor xenograft models.
  • Assessment of cell viability using MTT assay.
  • Investigation of interactions between FAM225A, miR-130a-5p, and CCNG1 using molecular biology techniques.

Main Results:

  • FAM225A was significantly upregulated in HCC tissues, cell lines, and sorafenib-resistant cells.
  • FAM225A knockdown reduced sorafenib resistance in HCC cells and tumor xenografts.
  • FAM225A directly interacts with miR-130a-5p, which targets CCNG1, modulating sorafenib sensitivity.

Conclusions:

  • The FAM225A/miR-130a-5p/CCNG1 network plays a key role in regulating sorafenib resistance in HCC.
  • Targeting this network offers a potential strategy to re-sensitize HCC to sorafenib treatment.
Keywords:
CCNG1FAM225Ahepatocellular carcinomamiR-130a-5psorafenib resistant

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.0K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K